We suggest to use analysis of Arch Biopartners fundamentals to see if markets are presently mispricing the company. We were able to break down twenty-six available fundamental indicators for Arch Biopartners, which can be compared to its peers. The stock experiences a moderate downward daily trend and can be a good diversifier. Check odds of Arch Biopartners to be traded at C$1.911 in 90 days. Key indicators impacting Arch Biopartners' financial strength include:
Understanding current and past Arch Biopartners Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Arch Biopartners' financial statements are interrelated, with each one affecting the others. For example, an increase in Arch Biopartners' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Arch Biopartners' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Arch Biopartners. Check Arch Biopartners' Beneish M Score to see the likelihood of Arch Biopartners' management manipulating its earnings.
Arch Biopartners Stock Summary
Arch Biopartners competes with Westaim Corp, Pulse Seismic, Quarterhill, and TECSYS. Arch Biopartners Inc., a biotechnology company, develops technologies for improving the health of patients. In addition, the company develops Borg, a Peptide-solid surface interface to inhibit biofilm formation and reduce corrosion and MetaMx synthetic molecules that targets brain tumor initiating cells and invasive glioma cells. ARCH BIOPARTNERS is traded on TSX Venture Exchange in Canada.
Foreign Associate
USA
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
You should never invest in Arch Biopartners without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Arch Stock, because this is throwing your money away. Analyzing the key information contained in Arch Biopartners' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Arch Biopartners Key Financial Ratios
There are many critical financial ratios that Arch Biopartners' investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Arch Biopartners reports annually and quarterly.
Comparative valuation techniques use various fundamental indicators to help in determining Arch Biopartners's current stock value. Our valuation model uses many indicators to compare Arch Biopartners value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Arch Biopartners competition to find correlations between indicators driving Arch Biopartners's intrinsic value. More Info.
Arch Biopartners is number one stock in return on asset category among its peers. It also is number one stock in profit margin category among its peers . At this time, Arch Biopartners' Net Loss is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Arch Biopartners' earnings, one of the primary drivers of an investment's value.
Arch Biopartners Systematic Risk
Arch Biopartners' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Arch Biopartners volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Arch Biopartners correlated with the market. If Beta is less than 0 Arch Biopartners generally moves in the opposite direction as compared to the market. If Arch Biopartners Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Arch Biopartners is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Arch Biopartners is generally in the same direction as the market. If Beta > 1 Arch Biopartners moves generally in the same direction as, but more than the movement of the benchmark.
Arch Biopartners Total Assets Over Time
Today, most investors in Arch Biopartners Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Arch Biopartners' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Arch Biopartners growth as a starting point in their analysis.
Arch Biopartners December 2, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Arch Biopartners help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Arch Biopartners. We use our internally-developed statistical techniques to arrive at the intrinsic value of Arch Biopartners based on widely used predictive technical indicators. In general, we focus on analyzing Arch Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Arch Biopartners's daily price indicators and compare them against related drivers.
When running Arch Biopartners' price analysis, check to measure Arch Biopartners' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Arch Biopartners is operating at the current time. Most of Arch Biopartners' value examination focuses on studying past and present price action to predict the probability of Arch Biopartners' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Arch Biopartners' price. Additionally, you may evaluate how the addition of Arch Biopartners to your portfolios can decrease your overall portfolio volatility.